Location
San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Time
7:30 PM – 9:00 PM — Educational Dinner Meeting
Meeting Room
Grand Ballroom G-M (Third Floor)
There is no registration fee for this event. However, preregistration is advised as seating is limited.
Faculty
Erika Hamilton, MD
Director, Breast and Gynecologic
Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Professor Sherene Loi, MBBS, PhD
Medical Oncologist, Breast Unit
Lab Head
Head, Breast Cancer Clinical Trials Unit
National Breast Cancer Foundation of
Australia Endowed Chair
Peter MacCallum Cancer Centre
Melbourne, Australia
Mark E Robson, MD
Chief, Breast Medicine Service
Attending Physician
Breast Medicine and Clinical Genetics
Services Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
MODULE 1: Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making
- Current indications for and optimal testing platforms to assess PD-L1 expression in patients with metastatic TNBC (mTNBC)
- Correlation between PD-L1 expression in immune cells and responsiveness to anti-PD-1/PD-L1 antibodies in TNBC; other exploratory biomarkers of potential response to immune checkpoint inhibition
- Indications for MSI testing in patients with mTNBC; implications of positive test results on patient outcomes and current management
- Incidence of BRCA1/2 alterations and other relevant genetic abnormalities in patients with and without a family history of BC
- Guideline-endorsed indications for genetic testing in patients with TNBC; similarities, differences and optimal use of available BRCA testing platforms
- Historical efficacy and safety outcomes with available therapies (capecitabine, eribulin, gemcitabine, platinums) for patients with advanced TNBC; optimal selection and sequencing of these agents in patients who are and are not candidates for biomarker-based therapy
MODULE 2: Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC
- Biologic rationale for the investigation of immune checkpoint inhibitors in BC
- Early research experience with the use of anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy for patients with mBC; activity in TNBC relative to other BC phenotypes
- Design, eligibility criteria and efficacy findings from the Phase III IMpassion130 trial evaluating atezolizumab with nab paclitaxel as first-line therapy for mTNBC
- Immune-related and other adverse events with combination therapy on the IMpassion130 study
- FDA approval of atezolizumab/nab paclitaxel for patients with PD-L1-positive unresectable locally advanced or metastatic TNBC; integration of this approach into clinical practice
- Ongoing Phase III studies of other anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy for patients with advanced TNBC (eg, IMpassion131, IMpassion132, KEYNOTE-355)
MODULE 3: Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC
- Phase III data sets supporting the FDA approvals for olaparib (OlympiAD) and talazoparib (EMBRACA) for patients with mBC and a BRCA germline mutation; patient selection for PARP inhibition in routine practice
- Effect of platinum exposure and number of lines of prior chemotherapy on the activity of PARP inhibitors in mTNBC
- Comparative incidence of side effects (gastrointestinal toxicities, anemia, thrombocytopenia, et cetera) associated with olaparib and/or talazoparib; optimal prevention and management strategies
- Biologic rationale for the investigation of novel combination strategies of PARP inhibitors and other systemic approaches (eg, chemotherapy, immune checkpoint inhibitors) in TNBC
- Available efficacy and safety results from the Phase III BROCADE-3 study of veliparib with carboplatin and paclitaxel for patients with HER2-negative locally advanced or metastatic BC and a BRCA germline mutation; potential clinical implications
- Available data with and ongoing investigation of PARP inhibition in the adjuvant and neoadjuvant settings
MODULE 4: Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials
- Efficacy and safety results from the Phase III KEYNOTE-522 trial documenting the benefit of neoadjuvant pembrolizumab with chemotherapy versus chemotherapy alone for TNBC
- Other ongoing randomized Phase III clinical trials evaluating the use of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in patients with localized TNBC
- Mechanisms of action of the novel antibody-drug conjugates sacituzumab govitecan and ladiratuzumab vedotin; early efficacy and safety data and ongoing evaluation in mTNBC
- Rationale for targeting the PI3K/AKT/mTOR pathway in TNBC; available data with and ongoing investigation of ipatasertib in combination with atezolizumab and chemotherapy for mTNBC
- Preliminary efficacy and safety data with the investigational CDK4/6 inhibitor trilaciclib in combination with gemcitabine and carboplatin for patients with mTNBC; future development plans
- Other promising novel agents and strategies under investigation
Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Evaluate published research findings, relevant clinical factors (eg, age, performance status, prior therapeutic exposure) and patient preferences in the selection and sequencing of available therapeutic agents for metastatic ER/PR-negative, HER2-negative breast cancer.
- Appreciate the biologic rationale for, available data with and potential long-term benefits of anti-PD-1/PD-L1 antibody therapy for patients with metastatic triple-negative breast cancer (mTNBC).
- Consider recently presented Phase III data documenting the efficacy of an anti-PD-L1 antibody combined with chemotherapy for newly diagnosed mTNBC, and use this information to prepare for the potential introduction of this approach into clinical practice.
- Assess the biologic rationale for ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for breast cancer in order to effectively communicate to patients the potential benefits of trial participation.
- Appraise published efficacy and safety data with the use of PARP inhibitors for metastatic breast cancer harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings for nonresearch clinical care.
- Recall the design of ongoing clinical trials evaluating other investigational PARP inhibitors and novel applications of PARP inhibitors alone or in combination with other systemic approaches (eg, immunotherapy, chemotherapy) for breast cancer, and counsel appropriate patients about availability and participation.
- Appreciate the mechanisms of action of, early data with and ongoing research efforts evaluating other novel agents and treatment strategies under development for patients with TNBC.
CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech and Merck.
San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom G-M (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center.
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. If you are interested in attending, please visit our onsite registration desk, which will open at 7:00 PM on Thursday, December 12. Our onsite registration desk will be located outside Grand Ballroom G-M on the third floor of the Marriott Rivercenter hotel (101 Bowie Street, San Antonio, TX 78205), which is within 1.5 blocks of the Henry B González Convention Center.
We will accept onsite registration until reaching the meeting room capacity. Please note, onsite registration does not guarantee participation in the session or meal service, and seating will be prioritized for clinicians in practice.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153 or +1 (305) 377-2828.
NOTICE:
This educational session has been approved by SABCS as an official adjunct CME satellite symposium, and registration for this event is independent of registration for SABCS.
|
